sampl
patient
rsv
infect
healthi
control
sampl
common
two
cohort
similarli
creat
two
cohort
compar
sampl
influenza
rsv
infect
patient
healthi
control
final
compar
hrv
sampl
healthi
control
remain
sampl
viral
bacteri
infect
use
valid
cohort
mv
figur
similar
approach
took
select
data
set
discov
mv
signatur
sought
repres
biolog
technic
heterogen
observ
popul
repres
phenotyp
divers
choos
sampl
follow
cohort
control
healthi
day
preinocul
bacteri
pneumonia
case
postinocul
influenza
pneumonia
chose
dataset
collect
center
differ
countri
repres
differ
biolog
confound
factor
popul
genet
treatment
protocol
infecti
agent
also
incorpor
technic
heterogen
sampl
choos
dataset
profil
use
differ
microarray
platform
identifi
five
dataset
consist
blood
sampl
satisfi
criteria
preinocul
sampl
influenza
use
control
sampl
postinocul
sampl
influenza
use
case
irrespect
whether
symptomat
asymptomat
inocul
bacteri
pneumonia
sampl
prevaccin
sampl
use
control
sever
influenza
day
postvaccin
sampl
use
case
sampl
patient
influenza
pneumonia
healthi
control
use
irrespect
day
sampl
taken
rest
sampl
dataset
bacteri
pneumonia
mixedpneumonia
noninfecti
systemat
inflammatori
respons
use
valid
im
figur
use
sampl
healthi
control
influenzainfect
sampl
sampl
rsvinfect
patient
use
valid
specif
im
influenza
infect
figur
appli
two
metaanalysi
method
describ
previou
public
supplementari
figur
supplementari
tabl
framework
analysi
subset
total
dataset
select
use
discoveri
cohort
describ
supplementari
tabl
analyz
use
two
metaanalysi
method
combin
effect
size
ii
combin
pvalu
estim
effect
size
gene
data
set
hedg
adjust
g
multipl
probe
map
gene
effect
size
gene
summar
use
fix
effect
inversevari
model
studyspecif
effect
size
gene
combin
singl
meta
effects
use
linear
combin
studyspecif
effect
size
fi
studyspecif
effect
size
weight
invers
varianc
correspond
studi
comput
meta
effects
pvalu
correct
multipl
hypothes
test
use
benjaminihochberg
fals
discoveri
rate
fdr
correct
signific
gene
identifi
use
zstatist
use
fisher
sum
log
method
metaanalysi
combin
pvalu
gene
sum
logarithm
onesid
hypothesi
test
pvalu
across
k
studi
compar
result
distribut
degre
freedom
dataset
larg
sampl
size
significantli
influenc
metaanalysi
result
therefor
perform
metaanalysi
remov
one
dataset
time
order
avoid
influenc
singl
dataset
identifi
mv
im
appli
metaanalysi
method
iter
use
fdr
fdr
iter
mv
im
respect
identifi
differenti
express
gene
overexpress
underexpress
across
viral
infect
overexpress
gene
across
influenzainfect
dataset
allow
signific
heterogen
identifi
mv
differ
virus
may
induc
variou
gene
differ
level
howev
ensur
signific
heterogen
p
effect
size
across
dataset
im
defin
mv
score
sampl
geometr
mean
normal
express
overexpress
gene
minu
underexpress
gene
defin
im
score
sampl
geometr
mean
normal
express
overexpress
gene
scale
center
mv
im
score
sampl
given
dataset
mean
standard
deviat
enabl
comparison
dataset
use
wilcoxonmannwhitney
anova
test
whether
statist
signific
differ
mv
im
score
two
group
dataset
contain
neg
valu
comput
geometr
mean
possibl
dataset
use
mean
normal
express
valu
comput
mv
im
score
perform
function
pathway
analysi
use
ipathwayguid
metaeffect
size
across
viral
infect
use
fold
chang
ipathwayguid
identifi
signific
pathway
use
fdr
threshold
identifi
signific
pathway
perform
network
analysi
influenzaspecif
gene
use
ipa
option
includ
direct
relationship
avoid
spuriou
connect
caus
indirect
relat
direct
relationship
ipa
result
public
cite
experiment
evid
interact
section
describ
dataset
use
analysi
order
accur
describ
dataset
descript
use
verbatim
correspond
manuscript
much
possibl
ioannidi
et
al
profil
blood
sampl
children
median
rang
rang
month
hospit
acut
rsv
influenza
infect
sampl
patient
collect
within
hour
hospit
exclud
children
suspect
proven
polymicrobi
infect
underli
chronic
medic
condit
immunodefici
receiv
system
steroid
immunomodulatori
therapi
control
sampl
collect
children
undergo
elect
surgic
procedur
outpati
clinic
visit
exclud
viral
coinfect
perform
nasopharyng
viral
cultur
subject
herberg
et
al
recruit
febril
children
year
respiratori
infect
collect
whole
blood
sampl
ramilo
et
al
profil
pbmc
young
patient
age
year
acut
infect
caus
common
human
pathogen
rna
viru
influenza
two
gramposit
bacteria
staphylococcu
aureu
streptococcu
pneumonia
gramneg
bacterium
escherichia
coli
patient
dataset
treat
accord
standard
hospit
protocol
antimicrobi
therapi
promptli
initi
emerg
depart
patient
treat
three
differ
drug
overal
set
drug
repres
potenti
confound
factor
analysi
studi
profil
sampl
use
three
type
microarray
two
manufactur
affymetrix
hg
hg
plu
illumina
repres
technic
variabl
parnel
et
al
recruit
patient
sever
communityacquir
pneumonia
requir
sever
intens
care
unit
icu
admiss
also
recruit
patient
noninfect
system
inflammatori
respons
syndrom
sir
healthi
control
sir
defin
presenc
least
two
follow
four
clinic
criteria
fever
hypothermia
temperatur
b
tachycardia
beatsmin
c
tachypnea
breathsmin
kpa
mm
hg
need
mechan
ventil
alter
white
blood
cell
count
presenc
band
form
pneumonia
defin
microbiolog
confirm
infect
lung
result
patient
fulfil
sir
criteria
first
sampl
patient
collect
within
initi
hour
admiss
icu
refer
day
patient
monitor
upto
day
access
longitudin
geneexpress
profil
recruit
patient
primari
viral
pneumonia
acut
phase
influenza
viru
ill
acut
respiratori
distress
unequivoc
alveolar
opacif
involv
two
lobe
neg
respiratori
blood
bacteri
cultur
admiss
icu
exclud
patient
older
year
younger
year
studi
avoid
immaturityag
immun
system
confus
factor
analysi
patient
confirm
infect
realtim
polymeras
chain
reaction
pcr
includ
studi
healthi
volunt
similar
age
patient
recruit
worker
univers
valladolid
spain
treatment
decis
patient
includ
corticosteroid
therapi
standard
decid
attend
physician
hrv
cohort
zaa
et
al
recruit
healthi
volunt
activ
screen
protocol
univers
virginia
charlottesvil
va
day
inocul
gmp
hrv
serotyp
inocul
intranas
subject
admit
quarantin
facil
hour
follow
hrv
inocul
remain
hour
follow
inocul
nasopharyng
np
lavag
sampl
obtain
subject
daili
hrv
titer
accur
gaug
success
time
hrv
inocul
follow
hour
inocul
subject
releas
quarantin
return
consecut
morn
sampl
acquisit
rsv
challeng
perform
retroscreen
virolog
ltd
london
day
inocul
dose
rsv
serotyp
inocul
intranas
per
standard
method
blood
np
lavag
collect
method
similar
hrv
cohort
continu
throughout
quarantin
due
incub
period
rsv
subject
releas
quarantin
hour
neg
rapid
rsv
antigen
detect
day
inocul
dose
influenza
dilut
inocul
intranas
per
standard
method
vari
dose
four
five
subject
receiv
dose
due
incub
period
subject
releas
quarantin
hour
blood
np
lavag
collect
continu
throughout
durat
quarantin
subject
receiv
oral
oseltamivir
roch
pharmaceut
mg
mouth
twice
daili
day
follow
inocul
neg
rapid
antigen
detect
time
discharg
mejia
et
al
perform
prospect
observ
studi
six
respiratori
season
includ
cohort
hospit
infant
year
old
rsv
hrv
influenza
infect
one
three
center
nationwid
children
hospit
columbu
ohio
turku
univers
turku
finland
children
medic
center
dalla
texa
us
children
document
bacteri
coinfect
includ
bacteremia
urinari
tract
infect
mening
acut
gastroenter
bacteri
pathogen
isol
steril
site
viral
coinfect
exclud
studi
also
exclud
children
congenit
heart
diseas
chronic
lung
diseas
immunodefici
prematur
week
system
steroid
treatment
within
week
present
control
sampl
obtain
healthi
children
undergo
elect
surgeri
involv
respiratori
tract
routin
outpati
visit
healthi
control
group
clinic
questionnair
use
children
comorbid
use
system
steroid
presenc
ill
within
week
prior
enrol
exclud
lastli
exclud
viral
coinfect
respiratori
sampl
test
viral
cultur
pcr
patient
control
influenza
strain
collect
whole
blood
sampl
hour
interv
inocul
symptom
record
twice
daili
use
modifi
standard
symptom
score
call
modifi
jackson
score
requir
subject
rank
symptom
upper
respiratori
infect
stuffi
nose
scratchi
throat
headach
cough
etc
scale
symptom
notic
bothersom
still
activ
bothersom
daili
activ
cohort
modifi
jackson
score
tabul
determin
subject
becam
symptomat
respiratori
viral
challeng
symptom
onset
defin
first
contigu
day
score
modifi
jackson
score
consecut
five
day
period
primari
indic
symptomat
viral
infect
subject
score
posit
qualit
viral
cultur
quantit
rtpcr
least
consecut
day
begin
hour
inocul
denot
symptomat
infect
subject
classifi
asymptomat
infect
symptom
score
less
five
day
observ
viral
shed
document
first
hour
subsequ
inocul
standard
symptom
score
tabul
end
studi
determin
attack
rate
time
maxim
symptom
tsang
et
al
healthi
volunt
age
enrol
nation
institut
health
nih
protocol
clinicaltrialsgov
healthi
volunt
screen
protocol
enrol
medic
histori
physic
examin
clinic
laboratori
studi
cbc
differenti
blood
chemistri
coagul
thrombosi
screen
pt
ptt
ddimer
cholesterol
panel
urinalysi
pregnanc
test
pregnant
individu
receiv
vaccin
taken
immun
modifi
medic
within
six
month
studi
entri
exclud
individu
meet
inclus
criteria
vaccin
fluvirin
season
influenza
novarti
pandem
sanofiaventi
vaccin
without
adjuv
blood
sampl
obtain
day
prior
vaccin
day
immedi
vaccin
post
vaccin
blood
sampl
drawn
fast
individu
process
within
minut
draw
supplementari
fig
refer
fig
im
score
increas
significantli
vaccin
respond
defin
use
microneutr
titer
instead
hai
titer
ab
chang
im
score
vaccin
respond
nonrespond
defin
base
microneutr
titer
femal
cohort
follow
influenza
vaccin
cd
chang
im
score
vaccin
respond
nonrespond
defin
base
microneutr
titer
male
cohort
follow
influenza
vaccin
